Nothing Special   »   [go: up one dir, main page]

Cao et al., 2014 - Google Patents

A metabonomics study of Chinese miniature pigs with acute liver failure treated with transplantation of placental mesenchymal stem cells

Cao et al., 2014

View PDF
Document ID
3752818891576973458
Author
Cao H
Ma J
Yang J
Su X
Chen D
Yu J
Pan Q
Shao L
Zhou P
Li J
Wang Y
Li L
Publication year
Publication venue
Metabolomics

External Links

Snippet

Metabonomics has become a highly sensitive and powerful tool for screening of biomarkers and elucidation of biochemical processes. Recently, we reported beneficial therapeutic effect of human placenta mesenchymal stem cells (hPMSCs) transplantation on d …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Similar Documents

Publication Publication Date Title
Angel et al. Enhanced sensitivity for high spatial resolution lipid analysis by negative ion mode matrix assisted laser desorption ionization imaging mass spectrometry
US10386371B2 (en) Metabolic flux measurement, imaging and microscopy
Miyamoto et al. Mass spectrometry imaging reveals elevated glomerular ATP/AMP in diabetes/obesity and identifies sphingomyelin as a possible mediator
Chetwynd et al. Collection and preparation of clinical samples for metabolomics
Newsom et al. Skeletal muscle phosphatidylcholine and phosphatidylethanolamine are related to insulin sensitivity and respond to acute exercise in humans
Grove et al. Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles1 [S]
Ressom et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis
Tahallah et al. Lipid mapping in human dystrophic muscle by cluster-time-of-flight secondary ion mass spectrometry imaging
Liu et al. Imaging of polar and nonpolar species using compact desorption electrospray ionization/postphotoionization mass spectrometry
De Guzman et al. Chronic caloric restriction partially protects against age-related alteration in serum metabolome
Mirnezami et al. Implementation of molecular phenotyping approaches in the personalized surgical patient journey
Chen et al. Metabolomics: a promising diagnostic and therapeutic implement for breast cancer
Phan et al. Laser desorption ionization mass spectrometry imaging of Drosophila brain using matrix sublimation versus modification with nanoparticles
JP2007524835A (en) Method for comparing the relative flow rates of two or more biomolecules in a single protocol in vivo
CA2498378C (en) Methods for measuring rates of reverse cholesterol transport in vivo, as an index of anti-atherogenesis
Castro-Perez et al. Identifying static and kinetic lipid phenotypes by high resolution UPLC–MS: unraveling diet-induced changes in lipid homeostasis by coupling metabolomics and fluxomics
Wolff et al. Sex differences in changes of protein synthesis with rapamycin treatment are minimized when metformin is added to rapamycin
Santos et al. Spatial metabolomics and its application in the liver
Lu et al. Sequential detection of lipids, metabolites, and proteins in one tissue for improved cancer differentiation accuracy
Jiang et al. Innovation in drug toxicology: Application of mass spectrometry imaging technology
Haberl et al. Accumulation of cholesterol, triglycerides and ceramides in hepatocellular carcinomas of diethylnitrosamine injected mice
Lee et al. In vitro tracking of intracellular metabolism-derived cancer volatiles via isotope labeling
Ou et al. Apolipoprotein AI mimetic peptide inhibits atherosclerosis by altering plasma metabolites in hypercholesterolemia
Araujo et al. Metabolomic studies of breast cancer in murine models: A review
Morad et al. Diagnostic value of 1H NMR-based metabolomics in acute lymphoblastic leukemia, acute myeloid leukemia, and breast cancer